The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
This article was originally published on MedicalXpress.com